Gewinnerbranchen der Jahre 2006 bis 2040 (Seite 7689)
eröffnet am 10.12.06 16:57:17 von
neuester Beitrag 16.02.24 09:33:08 von
neuester Beitrag 16.02.24 09:33:08 von
Beiträge: 94.068
ID: 1.099.361
ID: 1.099.361
Aufrufe heute: 6
Gesamt: 3.536.152
Gesamt: 3.536.152
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| heute 18:57 | 9458 | |
| vor 42 Minuten | 9048 | |
| 11.01.09, 16:18 | 7150 | |
| vor 51 Minuten | 6096 | |
| vor 51 Minuten | 5602 | |
| vor 1 Stunde | 5212 | |
| vor 30 Minuten | 4937 | |
| vor 1 Stunde | 4018 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 2. | 18.880,00 | +0,58 | 209 | |||
| 2. | 1. | 4,9385 | -28,07 | 182 | |||
| 3. | 4. | 6,9260 | -1,73 | 112 | |||
| 4. | 9. | 0,2060 | +3,78 | 66 | |||
| 5. | 6. | 159,98 | -2,43 | 54 | |||
| 6. | 12. | 5,6050 | -5,89 | 53 | |||
| 7. | 8. | 0,2380 | -46,88 | 49 | |||
| 8. | 3. | 37,16 | -24,58 | 43 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 35.294.837 von clearasil am 26.09.08 16:35:17irgendwie scheint die wamu-geschichte verbilligend auf die ma zu wirken.
kann gut sein das die kreditkarten demnächst weniger benutzt werden bzw. das die börse dies denkt. beides würde zu bewertungsabbau führen.
gutes unternehmen ,aber warten
kann gut sein das die kreditkarten demnächst weniger benutzt werden bzw. das die börse dies denkt. beides würde zu bewertungsabbau führen.
gutes unternehmen ,aber warten
Antwort auf Beitrag Nr.: 35.294.017 von benny_m am 26.09.08 15:57:00Pharma, Biotech, Medtech, Zigaretten, Nahrung ....
sozusagen mein investitionsschwerpunkt
sozusagen mein investitionsschwerpunkt
Antwort auf Beitrag Nr.: 35.293.776 von parti am 26.09.08 15:46:22hallo leute, ich hätte da mal eine frage. gibt es schon eine branche, die sich in den letzten tagen und wochen von dem allgemeinen trend entziehen konnte?
fast der ganze markt ist wesentlich stärker als die untergangsstimmung der medien.
ich bleib dabei wir sind in den indizes fast unten
fast der ganze markt ist wesentlich stärker als die untergangsstimmung der medien.
ich bleib dabei wir sind in den indizes fast unten
Antwort auf Beitrag Nr.: 35.293.595 von clearasil am 26.09.08 15:38:52@pontius: weißt du noch, was muslimische Geistliche mit den Mäusen machen???
vielleicht sollte man unter diesem aspekt ein investment in einen börsennotierten kammerjäger mit schwerpunkt nagetiere in islamischen ländern inbetracht ziehen. könnte ein growth market sein.
vielleicht sollte man unter diesem aspekt ein investment in einen börsennotierten kammerjäger mit schwerpunkt nagetiere in islamischen ländern inbetracht ziehen. könnte ein growth market sein.
Pharmaceuticals: Pfizer Is a Buy
by: Mike Havrilla posted on: September 25, 2008 | about stocks: ABT / JNJ / PFE / TEVA Font Size: PrintEmail
The accompanying table presents an overview of big pharma companies, presented in descending order by market cap. My favorite play in the space remains Pfizer (PFE), which I have written about previously and finally bought shares of yesterday at $17.90 with a dividend yield exceeding 7%.
Despite growth concerns and looming generic competition for Lipitor in late 2011, I bought shares of Pfizer yesterday as a value pick and turnaround play which operates in a defensive sector with a strong balance sheet. Also, the company is aggressively cutting costs and buying back its shares on the open market.
Despite weakness in most of the 14 big pharma stocks presented on the table, it is unlikely that any will be lobbying Congress for subsidized loans or be the next big Wall Street firm to fail given their strong balance sheets and the necessity of their products to many people.
The only companies posting stock price gains over the past year include Abbott Labs (ABT), Johnson & Johnson (JNJ), and Teva Pharma (TEVA) with an average loss of 15.6% for the entire group.
I like Pfizer as a turnaround value play since its 7% dividend yield is twice the group's average and it also trades at a discount to the average price-sales ratio [PSR] and forward price-earnings [PE] ratio for the group.
by: Mike Havrilla posted on: September 25, 2008 | about stocks: ABT / JNJ / PFE / TEVA Font Size: PrintEmail
The accompanying table presents an overview of big pharma companies, presented in descending order by market cap. My favorite play in the space remains Pfizer (PFE), which I have written about previously and finally bought shares of yesterday at $17.90 with a dividend yield exceeding 7%.
Despite growth concerns and looming generic competition for Lipitor in late 2011, I bought shares of Pfizer yesterday as a value pick and turnaround play which operates in a defensive sector with a strong balance sheet. Also, the company is aggressively cutting costs and buying back its shares on the open market.
Despite weakness in most of the 14 big pharma stocks presented on the table, it is unlikely that any will be lobbying Congress for subsidized loans or be the next big Wall Street firm to fail given their strong balance sheets and the necessity of their products to many people.
The only companies posting stock price gains over the past year include Abbott Labs (ABT), Johnson & Johnson (JNJ), and Teva Pharma (TEVA) with an average loss of 15.6% for the entire group.
I like Pfizer as a turnaround value play since its 7% dividend yield is twice the group's average and it also trades at a discount to the average price-sales ratio [PSR] and forward price-earnings [PE] ratio for the group.
Trading Spotlight
The Most Expensive Drugs Are Getting Even More Expensive
Posted by Jacob Goldstein
Specialty drugs — often sold by biotech companies, and used to treat complex conditions such as cancer — are some of the most expensive medicines on the market. As it turns out, their already high prices are rising much faster than inflation, and even faster than the prices of other prescription drugs.
Last year, the wholesale price of specialty drugs rose 8.7%, three times the rate of inflation. The price of non-specialty, branded drugs rose 7.4%, while the price of generic drugs fell by 9.6%.
Those figures come from a new AARP report (online here) and are based on prices of more than 140 specialty drugs commonly used by Medicare beneficiaries. The list includes products from big name biotech and pharma shops like Amgen, Genentech, Pfizer and Ortho Biotech, a J&J subsidary.
The price of specialty drugs can run to tens of thousands of dollars per patient per year. Drug makers explain the high prices by pointing to high research costs, small patient populations and the complexities of manufacturing biotech drugs. Even so, the prices have been getting plenty of pushback lately from patients, government officials and even the occasional Wall Street analyst wondering how high prices can go.
That hasn’t stopped companies from jacking up the prices of drugs already on the market: Among 112 commonly used specialty drugs that were on the market from Dec. ‘03 through Dec. ‘07, the average price rose by 42.9%, the survey found.
“Specialty drug makers continue to raise the costs of drugs that have already been developed and tested,” AARP VP John Rother said in a statement. “By doing so, they’re increasing the burden on people with chronic conditions who can least afford it, as well as employer-sponsored health plans and even the American taxpayer through increased Medicare spending.”
PhRMA, the drug industry trade group, didn’t immediately respond to the Health Blog’s request for comment.
Posted by Jacob Goldstein
Specialty drugs — often sold by biotech companies, and used to treat complex conditions such as cancer — are some of the most expensive medicines on the market. As it turns out, their already high prices are rising much faster than inflation, and even faster than the prices of other prescription drugs.
Last year, the wholesale price of specialty drugs rose 8.7%, three times the rate of inflation. The price of non-specialty, branded drugs rose 7.4%, while the price of generic drugs fell by 9.6%.
Those figures come from a new AARP report (online here) and are based on prices of more than 140 specialty drugs commonly used by Medicare beneficiaries. The list includes products from big name biotech and pharma shops like Amgen, Genentech, Pfizer and Ortho Biotech, a J&J subsidary.
The price of specialty drugs can run to tens of thousands of dollars per patient per year. Drug makers explain the high prices by pointing to high research costs, small patient populations and the complexities of manufacturing biotech drugs. Even so, the prices have been getting plenty of pushback lately from patients, government officials and even the occasional Wall Street analyst wondering how high prices can go.
That hasn’t stopped companies from jacking up the prices of drugs already on the market: Among 112 commonly used specialty drugs that were on the market from Dec. ‘03 through Dec. ‘07, the average price rose by 42.9%, the survey found.
“Specialty drug makers continue to raise the costs of drugs that have already been developed and tested,” AARP VP John Rother said in a statement. “By doing so, they’re increasing the burden on people with chronic conditions who can least afford it, as well as employer-sponsored health plans and even the American taxpayer through increased Medicare spending.”
PhRMA, the drug industry trade group, didn’t immediately respond to the Health Blog’s request for comment.
Antwort auf Beitrag Nr.: 35.294.659 von parti am 26.09.08 16:26:11heute sind wir dem Ende näher als noch vor ein paar Tagen 
wenn der Ausverkauf von letzter Woche nicht mehr unterschritten wird, würde ich das positiv sehen. Dazu bedürfte es aber auch mal einer vom breiten Markt getragenen Gegenbewegung.
Ob das zur Zeit drin ist ?
wenn der Ausverkauf von letzter Woche nicht mehr unterschritten wird, würde ich das positiv sehen. Dazu bedürfte es aber auch mal einer vom breiten Markt getragenen Gegenbewegung.
Ob das zur Zeit drin ist ?
irgendwie scheint die wamu-geschichte verbilligend auf die ma zu wirken. 
larry, bitte übernehmen Sie ?!
larry, bitte übernehmen Sie ?!
um eine mögliche trendwende im gesamtmarkt erkennen zu können
Antwort auf Beitrag Nr.: 35.293.776 von parti am 26.09.08 15:46:22warum so indizes-versessen? 
du bist hier im stockpickers-paradise-survival-thread
gruß c.
du bist hier im stockpickers-paradise-survival-thread
gruß c.
Durchsuchen
